Veru Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Note 4 - Revenue From Contracts With Customers (Tables)

Note 4 - Revenue From Contracts With Customers (Tables)

9 Months Ended

Jun. 30, 2024

Notes Tables

Disaggregation of Revenue [Table Text Block]

		*Three Months Ended*								*Nine Months Ended*
		*June 30,*								*June 30,*
		*2024*				*2023*				*2024*				*2023*
FC2
Global public health sector		$	3,402,328			$	2,478,031			$	8,447,329			$	7,249,315
U.S. prescription channel			551,542				863,379				1,782,568				5,172,543
Total FC2			3,953,870				3,341,410				10,229,897				12,421,858
ENTADFI			—				(225	)			—				13,088
Net revenues		$	3,953,870			$	3,341,185			$	10,229,897			$	12,434,946

Revenue from External Customers by Geographic Areas [Table Text Block]

		*Three Months Ended*								*Nine Months Ended*
		*June 30,*								*June 30,*
		*2024*				*2023*				*2024*				*2023*

United States		$	1,107,009			$	1,449,883			$	3,700,727			$	7,046,518
South Africa			—				612,000				1,177,200				1,941,678
Mozambique			1,317,480				*				2,172,840				*
Other			1,529,381				1,279,302				3,179,130				3,446,750
Net revenues		$	3,953,870			$	3,341,185			$	10,229,897			$	12,434,946